You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for CGP 52432
CGP 52432 is a potent, selective GABAB receptor antagonist (IC50 = 85 nM).
Sold with the permission of Novartis Pharma AG
Technical Data for CGP 52432
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for CGP 52432
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|water||3.84||10 with sonication|
Preparing Stock Solutions for CGP 52432
The following data is based on the product molecular weight 384.24. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||26.03 mL||130.13 mL||260.25 mL|
|0.5 mM||5.21 mL||26.03 mL||52.05 mL|
|1 mM||2.6 mL||13.01 mL||26.03 mL|
|5 mM||0.52 mL||2.6 mL||5.21 mL|
References for CGP 52432
References are publications that support the biological activity of the product.
Bonanno et al (1998) GABAB receptors as potential targets for drugs able to prevent excessive excitatory amino acid transmission in the spinal cord. Eur.J.Pharmacol. 362 143 PMID: 9874164
Lanza et al (1993) CGP 52432: a novel potent and selective GABAB autoreceptor antagonist in rat cerebral cortex. Eur.J.Pharmacol. 237 191 PMID: 8103461
Libri et al (1998) Blockade of GABAB receptors facilitates muscarinic agonist-induced epileptiform activity in immature rat piriform cortex in vitro. Naunyn Schmiedebergs Arch.Pharmacol. 358 168 PMID: 9750001
Froestl et al (1996) Potent, orally active GABAB receptor antagonists. Pharmacol.Rev.Comm. 8 127
If you know of a relevant reference for CGP 52432, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: CGP 52432, CGP 52432 supplier, Potent, selective, GABAB, antagonists, Receptors, CGP52432, 1246, Tocris Bioscience
22 Citations for CGP 52432
Citations are publications that use Tocris products. Selected citations for CGP 52432 include:
Jung Kim et al (2016) Vasculo-neuronal coupling: retrograde vascular communication to brain neurons The Journal of Neuroscience 14 12624 PMID: 27821575
Sargin et al (2016) Chronic social isolation reduces 5-HT neuronal activity via upregulated SK3 calcium-activated potassium channels Elife 5 e21416 PMID: 27874831
Jensen et al (2007) Presynaptic plasma membrane Ca2+ ATPase isoform 2a regulates excitatory synaptic transmission in rat hippocampal CA3. J Neurochem 579 85 PMID: 17170045
Yang et al (2013) PropF. inhibits superoxide production, elastase release, and chemotaxis in formyl peptide-activated human neutrophils by blocking formyl peptide receptor 1. J Immunol 190 6511 PMID: 23670191
Caiati et al (2012) Developmental regulation of CB1-mediated spike-time dependent depression at immature mossy fiber-CA3 synapses. Sci Rep 2 285 PMID: 22368777
Wu et al (2010) Correlated changes in NMDA receptor phosphorylation, functional activity, and sedation by chronic ethanol consumption. Development 115 1112 PMID: 20831600
Xiao et al (2012) The role of inhibition in oscillatory wave dynamics in the cortex. Eur J Neurosci 36 2201 PMID: 22805065
Li et al (2011) Synergistic activation of DA D1 and TrkB receptors mediate gain control of synaptic plasticity in the basolateral amygdala. PLoS One 6 e26065 PMID: 22022509
Adedoyin et al (2010) Endogenous N-acetylaspartylglutamate (NAAG) inhibits synaptic plasticity/transmission in the amygdala in a mouse inflammatory pain model. Mol Pain 6 60 PMID: 20860833
Song et al (2013) Different transporter systems regulate extracellular GABA from vesicular and non-vesicular sources. Front Cell Neurosci 7 23 PMID: 23494150
Venkataraman and Bartlett (2013) Postnatal development of synaptic properties of the GABAergic projection from the inferior colliculus to the auditory thalamus. J Neurophysiol 109 2866 PMID: 23536710
Moore et al (2009) Plasticity of burst firing induced by synergistic activation of metabotropic glutamate and acetylcholine receptors. Neuron 61 287 PMID: 19186170
Bragina et al (2015) Differential expression of metabotropic glutamate and GABA receptors at neocortical glutamatergic and GABAergic axon terminals. Front Cell Neurosci 9 345 PMID: 26388733
Lee et al (2015) Modulation of Spinal GABAergic Inhibition and Mechanical Hypersensitivity following Chronic Compression of Dorsal Root Ganglion in the Rat. Neural Plast 2015 924728 PMID: 26451259
Parker et al (2011) Attenuating GABA(A) receptor signaling in DA neurons selectively enhances reward learning and alters risk preference in mice. J Neurosci 31 17103 PMID: 22114279
Mans et al (2014) An acetylcholinesterase inhibitor, eserine, induces long-term depression at CA3-CA1 synapses in the hippocampus of adult rats. J Neurophysiol 112 2388 PMID: 25143547
Lam et al (2011) Leptin does not directly affect CNS serotonin neurons to influence appetite. J Physiol 13 584 PMID: 21531340
Vergassola et al (2018) Presynaptic mGlu1 Receptors Control GABAB Receptors in an Antagonist-Like Manner in Mouse Cortical GABAergic and Glutamatergic Nerve Endings. Front Mol Neurosci 11 324 PMID: 30279647
Dobson et al (2015) Caffeine Modulates Vesicle Release and Recovery at Cerebellar Parallel Fibre Terminals, Independently of Calcium and Cyclic AMP Signalling. J Pharmacol Exp Ther 10 e0125974 PMID: 25933382
Chacón et al (2012) Focal adhesion kinase regulates actin nucleation and neuronal filopodia formation during axonal growth. J Neurosci 139 3200 PMID: 22872087
Marrocco et al (2012) Anxiety-like behavior of prenatally stressed rats is associated with a selective reduction of glutamate release in the ventral hippocampus. PLoS One 32 17143 PMID: 23197707
Kelm et al (2008) The role of protein kinase A in the ethanol-induced increase in spontaneous GABA release onto cerebellar Purkinje neurons. J Neurophysiol 100 3417 PMID: 18945815
Do you know of a great paper that uses CGP 52432 from Tocris? Please let us know.
Reviews for CGP 52432
There are currently no reviews for this product. Be the first to review CGP 52432 and earn rewards!
Have you used CGP 52432?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
GABA Receptors Scientific Review
Written by Ian Martin, Norman Bowery and Susan Dunn, this review provides a history of the GABA receptor, as well as discussing the structure and function of the various subtypes and the clinical potential of receptor modulators; compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.